GHRP-2 vs GHRP-6: How Two GH Peptides Differ
Hexarelin and GHRPs
2-3x greater GH release from GHRP-2 versus GHRP-6 per microgram
GHRP-2 and GHRP-6 are the two most studied growth hormone releasing peptides. They activate the same receptor but produce meaningfully different hormonal and metabolic profiles.
Cheng et al., Life Sciences, 1997
Cheng et al., Life Sciences, 1997
View as imageGHRP-2 and GHRP-6 are synthetic hexapeptides that stimulate growth hormone release by activating the growth hormone secretagogue receptor (GHSR-1a), the same receptor that endogenous ghrelin binds. Both were developed in the 1980s and 1990s as research tools to probe the GH axis, and both remain among the most extensively studied growth hormone releasing peptides in the published scientific literature. They are not interchangeable. Despite binding the same receptor, GHRP-2 and GHRP-6 differ in GH-releasing potency, appetite effects, cortisol and prolactin stimulation, intracellular signaling pathways, and emerging cytoprotective applications. For the broader family of growth hormone releasing peptides including hexarelin, see the pillar article on hexarelin: the most potent growth hormone releasing peptide.
Key Takeaways
- GHRP-2 releases 2-3 times more growth hormone than GHRP-6 per microgram in rat pituitary cell assays, and both synergize with GHRH but not with each other (Cheng et al., 1997)
- GHRP-2 stimulates GH release through cAMP elevation (similar to GHRH), while GHRP-6 uses a cAMP-independent pathway despite binding the same receptor (Wu et al., 1996)
- GHRP-6 produces pronounced appetite stimulation in animal and human studies; GHRP-2 also increases food intake in healthy men but to a lesser degree (Laferrere et al., 2005)
- Both GHRP-2 and GHRP-6 raise ACTH and cortisol levels, unlike the more selective ipamorelin which releases GH without affecting the adrenal axis (Raun et al., 1998)
- GHRP-6 has demonstrated cardioprotective effects, preventing doxorubicin-induced myocardial damage in animal models (Berlanga-Acosta et al., 2024)
- GHRP-2 directly attenuates muscle atrophy gene expression (atrogin-1, MuRF1) in myocytes, acting through GHS-R independently of GH release (Yamamoto et al., 2008)
Structural Differences
GHRP-2 (pralmorelin, D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) and GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) are both synthetic hexapeptides derived from met-enkephalin analogs. They share three amino acids (Ala, D-Phe, Lys) in equivalent positions but differ at the N-terminal residues and at position 2. GHRP-2 incorporates D-2-naphthylalanine (D-2Nal) at position 2, a bulky hydrophobic residue that contributes to its higher receptor binding affinity. GHRP-6 has D-tryptophan at this position. Neither peptide retains opioid activity despite deriving from enkephalin scaffolds. The development history reflects a broader search for GH-releasing compounds: Cyril Bowers' laboratory screened thousands of met-enkephalin derivatives in the 1980s, selecting compounds based on GH release without opioid receptor activation. GHRP-6 emerged first as a useful research tool, while GHRP-2 was optimized later for greater potency. Both peptides are typically administered by subcutaneous injection at doses ranging from 100-300 mcg in research settings, with peak GH responses occurring 15-30 minutes after injection.
These structural differences produce measurably different pharmacology. Doi et al. (2004) characterized the complete pharmacological profile of GHRP-2 (developed as KP-102), documenting it as one of the most potent GH-releasing peptides with additional effects on appetite stimulation and cardiovascular parameters. The compound's potency exceeds GHRP-6 across multiple assays while maintaining a similar safety profile.[1]
GH Release: Potency and Mechanism
Cheng et al. (1997) conducted the definitive head-to-head comparison of GHRP-2 and GHRP-6 in rat primary pituitary cells. GHRP-2 stimulated 2-3 times more GH release than GHRP-6 at equivalent concentrations. Both peptides synergized with GHRH (growth hormone-releasing hormone) to produce GH release greater than either compound alone, but GHRP-2 and GHRP-6 did not synergize with each other. This mutual non-synergy confirmed that the two peptides act through the same receptor rather than through separate pathways.[2]
Wu et al. (1996) revealed a more surprising divergence: despite sharing a receptor, GHRP-2 and GHRP-6 activate different intracellular signaling cascades. GHRP-2 elevated intracellular cAMP levels in pituitary cells, a mechanism it shares with GHRH. GHRP-6, by contrast, released GH through a cAMP-independent pathway. This dissociation between receptor binding and downstream signaling means the two peptides likely stabilize different conformational states of GHSR-1a, triggering distinct intracellular effectors even though both activate the same receptor protein.[3]
This signaling divergence has practical implications. The cAMP pathway that GHRP-2 engages is the same pathway used by GHRH, which may explain both GHRP-2's greater GH-releasing potency and its additive (rather than synergistic) relationship with GHRH at high doses. GHRP-6's cAMP-independent mechanism, meanwhile, may preserve its synergy with GHRH across a wider dose range because the two signals converge on different intracellular nodes. This is an example of biased agonism: two ligands binding the same receptor can stabilize different receptor conformations, triggering distinct G-protein or beta-arrestin signaling cascades downstream. The phenomenon is well documented for other G-protein-coupled receptors and explains how structurally similar compounds can produce qualitatively different biological effects despite sharing a binding site.
The practical consequence for researchers combining GHRPs with GHRH is that GHRP-6 plus GHRH produces genuine synergy (the combined effect exceeds the sum of individual effects), while GHRP-2 plus GHRH is additive at best, because both are already engaging the cAMP pathway. In research protocols that aim to maximize GH release, the GHRP-6/GHRH combination may therefore produce higher peak GH levels than GHRP-2/GHRH despite GHRP-2's greater standalone potency.
Appetite and Food Intake
GHRP-6 is widely recognized for producing intense hunger. This is a direct pharmacological consequence of GHSR-1a activation in the hypothalamic arcuate nucleus, the same mechanism by which endogenous ghrelin stimulates appetite before meals. GHRP-6's appetite-stimulating properties have been extensively documented in animal models, and it serves as a standard pharmacological tool for studying ghrelin-mediated orexigenic signaling. For how GHRPs activate the ghrelin receptor at a molecular level, see how GHRPs activate the ghrelin receptor to release growth hormone.
GHRP-2 also increases food intake, but the effect is less dramatic. Laferrere et al. (2005) demonstrated that intravenous GHRP-2 increased food intake and hunger ratings in healthy men alongside GH release, confirming the orexigenic effect is present but quantitatively different from GHRP-6. The study directly compared GHRP-2 to ghrelin and found overlapping but non-identical appetite profiles, with GHRP-2 producing slightly less subjective hunger at GH-equivalent doses.[4]
The appetite difference between the two peptides may relate to GHRP-6's interaction with the CD36 scavenger receptor, a second binding target not shared by GHRP-2. Sabatino et al. (2011) mapped the structure-activity relationships of GHRP-6 azapeptide ligands at CD36, demonstrating that this receptor pathway contributes to GHRP-6's broader metabolic effects beyond GH release alone.[5] For the wider context of how hunger hormones drive appetite, see GHRP-6 and hunger: why this peptide makes you ravenous.
Cortisol, ACTH, and Prolactin
Neither GHRP-2 nor GHRP-6 is selective for GH release. Both stimulate ACTH and cortisol secretion, and both raise prolactin levels. This non-selectivity distinguishes them from ipamorelin, the first growth hormone secretagogue shown to release GH without affecting cortisol, prolactin, or ACTH even at doses 100 times the effective GH-releasing dose.[6]
Arvat et al. (1997) directly compared GHRP-2 and hexarelin (a related GHRP) in healthy men, measuring GH, prolactin, ACTH, and cortisol responses alongside GHRH, TRH, and CRH controls. Both GHRP-2 and hexarelin raised ACTH and cortisol levels. GHRP-2 produced somewhat lower cortisol elevation than hexarelin at equivalent GH-releasing doses, but the adrenal stimulation remained pharmacologically relevant. Prolactin increases were modest with both peptides.[7]
Kimura et al. (2010) showed that GHRP-2 produced both concordant and discordant ACTH responses in clinical diagnostic testing, meaning the cortisol response to GHRP-2 was not always proportional to its ACTH stimulation. This unpredictability adds complexity to interpreting GHRP-2's effects on the hypothalamic-pituitary-adrenal axis and is relevant for its occasional clinical use as a diagnostic tool for adrenal function testing.[8]
The cortisol stimulation from both peptides is a practical consideration. Repeated administration elevates baseline cortisol over time. For research involving chronic dosing, this effect must be monitored and may limit the therapeutic window. Ipamorelin's selectivity advantage is directly attributable to resolving this limitation. In clinical practice, GHRP-2 (under the name pralmorelin) has been approved in Japan as a diagnostic agent for growth hormone deficiency, where its reliable ACTH and cortisol stimulation is actually useful for assessing hypothalamic-pituitary-adrenal axis integrity alongside GH reserve in a single test.
Cytoprotective Effects: GHRP-6's Unexpected Advantage
GHRP-6 has accumulated a substantial body of evidence for organ-protective effects that extend far beyond growth hormone release. These effects appear to operate partly through GHSR-1a and partly through CD36 activation.
Berlanga-Acosta et al. (2024) demonstrated that GHRP-6 prevented doxorubicin-induced myocardial damage and extra-cardiac tissue damage by activating prosurvival signaling cascades. Doxorubicin (a widely used chemotherapy agent) causes dose-dependent cardiotoxicity that limits its clinical utility. GHRP-6 pretreatment protected heart tissue, liver, and kidney from doxorubicin's oxidative damage, positioning GHRP-6 as a potential cardioprotective adjunct during chemotherapy.[9]
Qiu et al. (2008) showed GHRP-6 improved gastroparesis (delayed stomach emptying) in diabetic rat models by stimulating gastric motility through ghrelin receptor activation. The therapeutic effect was comparable to exogenous ghrelin itself, establishing GHRP-6 as a prokinetic agent independent of its GH-releasing properties. This gastroprokinetic activity aligns with the known role of endogenous ghrelin in coordinating the migrating motor complex, the wave-like contractions that sweep residual food through the stomach during fasting. GHRP-6's ability to restore this motility pattern in diabetic models has generated interest in it as a potential therapeutic for diabetic gastroparesis, a condition with limited treatment options.[10]
GHRP-2 has its own protective profile, though it has been studied less extensively in this context. Granado et al. (2005) demonstrated anti-inflammatory effects of GHRP-2 in arthritic rats. GHRP-2 reduced joint inflammation and cartilage destruction through cytokine suppression, suggesting it engages anti-inflammatory signaling pathways distinct from its GH-releasing activity.[11]
Direct Muscle Effects
Both GHRPs have muscle-protective actions, but through different mechanisms.
Yamamoto et al. (2008) showed that GHRP-2 directly attenuated dexamethasone-induced muscle atrophy gene expression in myocytes. The compound suppressed upregulation of atrogin-1 and MuRF1 (two key ubiquitin ligases in the muscle wasting cascade) through GHS-R activation. This was a direct myocyte effect, not mediated through GH or IGF-1 release. The finding suggests GHRP-2 has anti-catabolic properties at the muscle fiber level that operate independently of its systemic hormonal effects.[12]
GHRP-6's muscle effects are less direct. Its primary influence on muscle tissue operates through GH and IGF-1 elevation (the traditional anabolic axis) and through appetite stimulation that increases caloric intake. In cachexia and wasting models, GHRP-6's pronounced appetite drive can be an advantage: increasing caloric intake provides the substrate for muscle protein synthesis while GH elevation activates the anabolic signaling cascade. GHRP-2's direct anti-catabolic action on muscle cells, by contrast, operates even without increased food intake, making it potentially more useful in situations where appetite stimulation is impractical or undesirable. The CD36-mediated cytoprotective pathways may also contribute to GHRP-6's muscle preservation under stress conditions, but direct myocyte studies comparable to the GHRP-2 work by Yamamoto et al. are limited.
For how growth hormone peptides affect body composition more broadly, see can growth hormone peptides build muscle?. For the oral secretagogue alternative, see MK-677 (ibutamoren).
Clinical Context and Diagnostic Use
GHRP-2 has achieved one clinical application that GHRP-6 has not: regulatory approval as a diagnostic tool. Under the name pralmorelin (marketed as GHRP Kaken in Japan), GHRP-2 is approved for assessing growth hormone deficiency. Patients receive a standardized intravenous injection and their GH response is measured at timed intervals. A blunted response indicates GH deficiency. The test is considered more convenient than the insulin tolerance test (the previous gold standard) because it does not require inducing hypoglycemia, which carries risks in patients with cardiovascular disease or seizure disorders.
GHRP-6 has no comparable regulatory approval anywhere, though it has been used as an investigational diagnostic tool in endocrinology research. Both peptides have been used extensively in clinical research to study the GH axis, pulsatile GH secretion, and the interaction between GHRH and GHS pathways. Their widespread availability as research reagents and their well-characterized pharmacology make them standard reference compounds in growth hormone physiology research.
Cabrales et al. (2013) conducted a formal pharmacokinetic study of GHRP-6 in nine healthy male volunteers, establishing baseline absorption, distribution, and elimination parameters for the compound. The study provided the reference pharmacokinetic data needed for designing clinical protocols using GHRP-6, filling a gap in the formal characterization of a peptide that had been used in research for decades.[13]
Summary Comparison Table
| Feature | GHRP-2 | GHRP-6 |
|---|---|---|
| GH potency | Higher (2-3x) | Lower |
| Signaling | cAMP-dependent | cAMP-independent |
| Appetite stimulation | Moderate | Strong |
| Cortisol/ACTH | Elevated | Elevated |
| Prolactin | Modestly elevated | Modestly elevated |
| CD36 binding | Minimal | Yes |
| Cardioprotection | Not established | Strong preclinical evidence |
| Anti-atrophy | Direct myocyte action | Primarily via GH/IGF-1 |
| Gastroparesis | Not studied | Therapeutic in animal models |
| Anti-inflammatory | Demonstrated in arthritis | Via CD36 cytoprotection |
The Bottom Line
GHRP-2 and GHRP-6 are structurally similar hexapeptides that both release growth hormone through GHSR-1a activation, but their pharmacological profiles diverge in clinically relevant ways. GHRP-2 is the more potent GH releaser with direct anti-atrophy effects on muscle cells, while GHRP-6 produces stronger appetite stimulation and has a broader cytoprotective portfolio through its additional CD36 receptor engagement. Both raise cortisol and ACTH, a non-selective effect that distinguishes them from ipamorelin. Neither peptide is inherently superior; they represent different pharmacological trade-offs within the same receptor family.